The Challenges of Vaccine Development Against Betacoronaviruses : Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector
To design an effective and safe vaccine against betacoronaviruses, it is necessary to elicit a combination of strong humoral and cell-mediated immune responses as well as to minimize the risk of antibody-dependent enhancement of viral infection. This phenomenon was observed in animal trials of experimental vaccines against SARS-CoV-1 and MERS-CoV that were developed based on inactivated coronavirus or vector constructs expressing the spike protein (S) of the virion. The substitution and glycosylation of certain amino acids in the antigenic determinants of the S-protein, as well as its conformational changes, can lead to the same effect in a new experimental vaccine against SARS-CoV-2. This review outlines approaches for developing vaccines against the new SARS-CoV-2 coronavirus that are based on non-pathogenic viral vectors. For efficient prevention of infections caused by respiratory pathogens the ability of the vaccine to stimulate mucosal immunity in the respiratory tract is important. Such a vaccine can be developed using non-pathogenic Sendai virus vector, since it can be administered intranasally and induce a mucosal immune response that strengthens the antiviral barrier in the respiratory tract and provides reliable protection against infection. The mucosal immunity and the production of IgA antibodies accompanying its development reduces the likelihood of developing an antibody-dependent infection enhancement, which is usually associated only with immunopathological IgG antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Molekuliarnaia biologiia - 54(2020), 6 vom: 26. Nov., Seite 922-938 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Zaichuk, T A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.12.2020 Date Revised 14.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.31857/S0026898420060154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318423618 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318423618 | ||
| 003 | DE-627 | ||
| 005 | 20231225165325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.31857/S0026898420060154 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318423618 | ||
| 035 | |a (NLM)33276356 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Zaichuk, T A |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Challenges of Vaccine Development Against Betacoronaviruses |b Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2020 | ||
| 500 | |a Date Revised 14.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To design an effective and safe vaccine against betacoronaviruses, it is necessary to elicit a combination of strong humoral and cell-mediated immune responses as well as to minimize the risk of antibody-dependent enhancement of viral infection. This phenomenon was observed in animal trials of experimental vaccines against SARS-CoV-1 and MERS-CoV that were developed based on inactivated coronavirus or vector constructs expressing the spike protein (S) of the virion. The substitution and glycosylation of certain amino acids in the antigenic determinants of the S-protein, as well as its conformational changes, can lead to the same effect in a new experimental vaccine against SARS-CoV-2. This review outlines approaches for developing vaccines against the new SARS-CoV-2 coronavirus that are based on non-pathogenic viral vectors. For efficient prevention of infections caused by respiratory pathogens the ability of the vaccine to stimulate mucosal immunity in the respiratory tract is important. Such a vaccine can be developed using non-pathogenic Sendai virus vector, since it can be administered intranasally and induce a mucosal immune response that strengthens the antiviral barrier in the respiratory tract and provides reliable protection against infection. The mucosal immunity and the production of IgA antibodies accompanying its development reduces the likelihood of developing an antibody-dependent infection enhancement, which is usually associated only with immunopathological IgG antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ADE | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-1 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sendai virus | |
| 650 | 4 | |a antibody-dependent enhancement | |
| 650 | 4 | |a conservative antigenic determinants | |
| 650 | 4 | |a murine respirovirus | |
| 650 | 4 | |a vaccine vector | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Nechipurenko, Y D |e verfasserin |4 aut | |
| 700 | 1 | |a Adzhubey, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Onikienko, S B |e verfasserin |4 aut | |
| 700 | 1 | |a Chereshnev, V A |e verfasserin |4 aut | |
| 700 | 1 | |a Zainutdinov, S S |e verfasserin |4 aut | |
| 700 | 1 | |a Kochneva, G V |e verfasserin |4 aut | |
| 700 | 1 | |a Netesov, S V |e verfasserin |4 aut | |
| 700 | 1 | |a Matveeva, O V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molekuliarnaia biologiia |d 1975 |g 54(2020), 6 vom: 26. Nov., Seite 922-938 |w (DE-627)NLM000033979 |x 0026-8984 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2020 |g number:6 |g day:26 |g month:11 |g pages:922-938 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.31857/S0026898420060154 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2020 |e 6 |b 26 |c 11 |h 922-938 | ||